GlassScriptPhysician profile
David Kheradyar
NPI 1518917640
$94,379.63
in general payments reported to CMS, 2019-2025
51 companies · $3,996 in 2025
The $3,996 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $16K · 2021: $14K · 2022: $15K · 2023: $12K · 2024: $6,651 · 2025: $3,996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $9,904 · Travel and Lodging: $543 · Consulting Fee: $413 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,637.61 |
| Food and Beverage | $9,903.58 |
| Travel and Lodging | $543.00 |
| Consulting Fee | $413.00 |
| Education | $105.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $80,965.42 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Novartis Pharmaceuticals Corporation | $1,814.82 | 2019-2025 | |
| Ucb, INC. | $1,120.38 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Abbvie INC. | $1,114.89 | 2021-2025 | |
| Genzyme Corporation | $1,105.38 | 2019-2024 | |
| Emd Serono, INC. | $690.11 | 2019-2025 | Mavenclad |
| Tg Therapeutics, INC. | $547.84 | 2024-2025 | |
| Celgene Corporation | $543.09 | 2022-2025 | Zeposia |
| Sk Life Science, INC. | $527.65 | 2020-2025 | Xcopri |
| Lundbeck LLC | $515.54 | 2023-2025 | Vyepti, Rexulti |
| Pfizer INC. | $470.36 | 2019-2025 | |
| Mdd US Operations, LLC | $419.61 | 2020-2025 | Gocovri, Gocovri |
| Otsuka America Pharmaceutical, INC. | $350.23 | 2023-2025 | Rexulti, Nuedexta |
| Amneal Pharmaceuticals LLC | $346.83 | 2019-2025 | Crexont, Rytary |
| Lilly USA, LLC | $338.81 | 2020-2025 | Emgality, Kisunla |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $286.98 | 2019-2020 | |
| Argenx US, INC. | $284.48 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $264.69 | 2019-2025 | Uplizna |
| Neurelis, INC. | $201.26 | 2023-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $187.91 | 2019-2025 | Nuplazid |
| Eisai INC. | $168.69 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $155.53 | 2024-2025 | Ponvory |
| Allergan, INC. | $139.41 | 2020 | |
| Tanabe Pharma America, INC. | $127.94 | 2022-2025 | Radicava |
| Catalyst Pharmaceuticals, INC. | $123.42 | 2021-2024 | Firdapse, Fycompa |
| Teva Pharmaceuticals USA, INC. | $118.96 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.80 | 2022 | |
| Livanova USA, INC. | $114.46 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Alnylam Pharmaceuticals INC. | $111.79 | 2019-2024 | Amvuttra |
| Abbott Laboratories | $110.61 | 2022 | |
| Mallinckrodt Hospital Products INC. | $93.92 | 2024-2025 | Acthar |
| Neurocrine Biosciences, INC. | $88.69 | 2019-2024 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $86.03 | 2022-2025 | Ultomiris |
| Avanir Pharmaceuticals, INC. | $79.05 | 2019 | |
| Horizon Therapeutics Plc | $76.78 | 2022-2023 | Uplizna |
| Aucta Pharmaceuticals, INC. | $73.14 | 2024-2025 | Motpoly Xr |
| Cycle Pharmaceuticals INC | $65.15 | 2025 | Bafiertam, Tascenso Odt |
| Ani Pharmaceuticals, INC. | $59.83 | 2024 | Purified Cortrophin Gel |
| Acorda Therapeutics, INC | $47.83 | 2019-2020 | |
| Boston Scientific Corporation | $44.64 | 2024 | |
| Jazz Pharmaceuticals INC. | $44.26 | 2023-2024 | |
| Harmony Biosciences LLC | $39.30 | 2024 | |
| Sumitomo Pharma America, INC. | $37.14 | 2023 | Aptiom |
| Supernus Pharmaceuticals, INC. | $27.96 | 2019 | |
| Banner Life Sciences, LLC | $24.35 | 2022 | |
| Kyowa Kirin, INC. | $22.32 | 2024 | Nourianz |
| Janssen Pharmaceuticals, INC | $19.92 | 2023 | Ponvory |
| Sanofi-Aventis U.S. LLC | $19.35 | 2020 | |
| Vertiflex, INC. | $18.06 | 2019 | |
| Genentech USA, INC. | $14.48 | 2025 | Ocrevus Zunovo |
| Strongbridge US INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kheradyar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.